[go: up one dir, main page]

WO2002048334A3 - P450rai-2 (p450 cytochrome 26b), codage de molecules d'acides nucleiques et leurs methodes d'utilisation - Google Patents

P450rai-2 (p450 cytochrome 26b), codage de molecules d'acides nucleiques et leurs methodes d'utilisation Download PDF

Info

Publication number
WO2002048334A3
WO2002048334A3 PCT/CA2001/001805 CA0101805W WO0248334A3 WO 2002048334 A3 WO2002048334 A3 WO 2002048334A3 CA 0101805 W CA0101805 W CA 0101805W WO 0248334 A3 WO0248334 A3 WO 0248334A3
Authority
WO
WIPO (PCT)
Prior art keywords
p450rai
trans
methods
cytochrome
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2001/001805
Other languages
English (en)
Other versions
WO2002048334A2 (fr
Inventor
Jay A White
P Martin Petkovich
Glenville Jones
Heather Ramshaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytochroma Inc
Original Assignee
Cytochroma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2000/001493 external-priority patent/WO2001044443A2/fr
Application filed by Cytochroma Inc filed Critical Cytochroma Inc
Priority to CA 2431640 priority Critical patent/CA2431640A1/fr
Priority to AU2002215776A priority patent/AU2002215776A1/en
Priority to US10/433,485 priority patent/US7115558B2/en
Publication of WO2002048334A2 publication Critical patent/WO2002048334A2/fr
Publication of WO2002048334A3 publication Critical patent/WO2002048334A3/fr
Anticipated expiration legal-status Critical
Priority to US11/498,250 priority patent/US7579329B2/en
Priority to US12/546,450 priority patent/US20100008902A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un nouvel acide tout-trans rétinoïque inductible d'acide tout-trans rétinoïque métabolisant le cytochrome P450, appelé P450RAI-2, qui est principalement exprimé dans le cerveau, en particulier dans le cervelet. Il est également exprimé dans les tissus pulmonaires sains ou tumoraux ainsi que dans les cellules du cancer du sein et peut avoir une corrélation avec le cancer des poumons et du sein. Le P450RAI-2 humain présente une homologie d'acides aminés d'au moins 42 % avec le P450RAI-1 humain. Lorsqu'il est transfecté dans des cellules COS-1, il entraîne une conversion rapide de tous les acides tout-trans rétinoïques dans plus de métabolites polaires comprenant les produits inactifs 4-oxo-RA, 4-OH-RA et 18-OH-RA. De plus, P450RAI-2, comme P450RAI-1, est aussi inductible dans certaines lignées de cellules de culture exposées à l'acide tout-trans rétinoïque. Par ailleurs, l'invention concerne des méthodes d'utilisation de ces nouveaux polynucléotide, polypeptide, fragments et inhibiteurs de ceux-ci, notamment dans le traitement de troubles dermatologiques, du cancer et de certains troubles cérébraux.
PCT/CA2001/001805 1999-12-16 2001-12-17 P450rai-2 (p450 cytochrome 26b), codage de molecules d'acides nucleiques et leurs methodes d'utilisation Ceased WO2002048334A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA 2431640 CA2431640A1 (fr) 2000-12-15 2001-12-17 P450rai-2 (p450 cytochrome 26b), codage de molecules d'acides nucleiques et leurs methodes d'utilisation
AU2002215776A AU2002215776A1 (en) 2000-12-15 2001-12-17 P450rai-2 (p450 cytochrome 26b), encoding nucleic acid molecules and methods and uses thereof
US10/433,485 US7115558B2 (en) 1999-12-16 2001-12-17 P450RAI-2(P450 Cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof
US11/498,250 US7579329B2 (en) 1999-12-16 2006-08-03 P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof
US12/546,450 US20100008902A1 (en) 1999-12-16 2009-08-24 P450rai-2 (p450 cytochrome 26b), encoding nucleic acid molecules and methods and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CAPCT/CA00/01493 2000-12-15
PCT/CA2000/001493 WO2001044443A2 (fr) 1999-12-16 2000-12-15 Proteine p450rai-2 et proteines associees

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2000/001493 Continuation-In-Part WO2001044443A2 (fr) 1999-12-16 2000-12-15 Proteine p450rai-2 et proteines associees

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10433485 A-371-Of-International 2001-12-17
US11/498,250 Continuation US7579329B2 (en) 1999-12-16 2006-08-03 P450RAI-2 (P450 cytochrome 26B), encoding nucleic acid molecules and methods and uses thereof

Publications (2)

Publication Number Publication Date
WO2002048334A2 WO2002048334A2 (fr) 2002-06-20
WO2002048334A3 true WO2002048334A3 (fr) 2002-12-19

Family

ID=4143116

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001805 Ceased WO2002048334A2 (fr) 1999-12-16 2001-12-17 P450rai-2 (p450 cytochrome 26b), codage de molecules d'acides nucleiques et leurs methodes d'utilisation

Country Status (2)

Country Link
AU (1) AU2002215776A1 (fr)
WO (1) WO2002048334A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0217631D0 (en) * 2002-07-30 2002-09-11 Inpharmatica Ltd Proteins
WO2005058301A1 (fr) 2003-12-17 2005-06-30 Allergan, Inc. Procedes permettant de traiter des troubles sensibles au retinoide au moyen d'inhibiteurs selectifs de cyp26a et de cyp26b

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049815A1 (fr) * 1996-06-21 1997-12-31 Queen's University At Kingston Proteines metabolisant le retinoide

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997049815A1 (fr) * 1996-06-21 1997-12-31 Queen's University At Kingston Proteines metabolisant le retinoide

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL EBI; 12 March 1999 (1999-03-12), SULSTON J.E., WATERSTON R.: "Homo sapiens BAC clone RP11-493L16 from 2, complete cds", XP002168113 *
MILLER WILSON H JR: "The emerging role of retinoids and retinoic acid metabolism blocking agents in the treatment of cancer.", CANCER, vol. 83, no. 8, 15 October 1998 (1998-10-15), pages 1471 - 1482, XP002213936, ISSN: 0008-543X *
NJAR V C O ET AL: "Potent inhibition of retinoic acid metabolism enzyme(s) by novel azolyl retinoids", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 17, September 2000 (2000-09-01), pages 1905 - 1908, XP004214134, ISSN: 0960-894X *
WHITE JAY A ET AL: "Identification of the human cytochrome P450, P450RAI-2, which is predominantly expressed in the adult cerebellum and is responsible for all-trans-retinoic acid metabolism.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 12, 6 June 2000 (2000-06-06), June 6, 2000, pages 6403 - 6408, XP002168088, ISSN: 0027-8424 *

Also Published As

Publication number Publication date
WO2002048334A2 (fr) 2002-06-20
AU2002215776A1 (en) 2002-06-24

Similar Documents

Publication Publication Date Title
WO2004080533A8 (fr) Appareil et procede d'application de signaux electriques pour modifier l'expression genique dans le tissu cardiaque
EP0883344A4 (fr) Molecules therapeutiques produites par trans-epissure
AU2003296958A1 (en) Therapeutic retroviral vectors for gene therapy
MXPA03001984A (es) Variantes de factor vii de coagulacion humano.
EP1642559A3 (fr) Utilisation de créatine et/ou de dérives de créatine dans des préparations cosmetiques ou dermatologues
WO2002060317A3 (fr) Compositions et methodes pour le traitement et le diagnostic du cancer du pancreas
WO2001072295A3 (fr) Compositions et methodes pouvant traiter ou diagnostiquer le cancer du poumon
WO2005000894A3 (fr) Molecules de liaison pour traiter les malignites de cellules myeloides
WO2002074156A3 (fr) Compositions et procedes de therapie et de diagnostic du cancer du colon
WO2001096388A8 (fr) Compositions et procedes servant a traiter et a diagnostiquer le cancer du colon
AU2003266214A1 (en) Human coagulation factor vii polypeptides
WO2001096390A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du colon
WO2002064748A3 (fr) Cellules souches adultes totipotentes, sources de ces cellules, procedes d'obtention et de maintien de ces dernieres, procedes de differentiation de ces cellules, procedes d'utilisation correspondants et cellules derivees des cellules susmentionnees
WO2006124892A3 (fr) Modulateurs de la toxicite induite par l'alpha-synucleine
WO2002004514A3 (fr) Compositions et procedes pour le traitement et le diagnostic du cancer du poumon
AU2001277539A1 (en) Pre-adipose cell lines
ATE374251T1 (de) Zusammensetzungen zur gentherapie von diabetes
TW200407425A (en) Human coagulation factor VII polypeptides
WO2001070977A3 (fr) Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
WO2002020762A3 (fr) Molecules analogues au recepteur du tnf et ses utilisations
WO2003037267A3 (fr) Compositions et methodes de traitement et de diagnostic du cancer des poumons
WO2003033678A3 (fr) Methodes d'utilisation d'inhibiteurs de la desacetylase afin de stimuler la differenciation et la regenerescence cellulaires
WO2001044443A3 (fr) Proteine p450rai-2 et proteines associees
WO2003087338A3 (fr) Molecules de tyrosine kinase du recepteur her-2 et utilisations associees
WO2001077168A3 (fr) Compositions et procedes permettant de traiter et de diagnostiquer le cancer du poumon

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2431640

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10433485

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP